PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2446520-1 1987 The present study was undertaken to evaluate the effect of fenoterol, a selective beta 2-adrenergic agonist, on basophil histamine release. Histamine 121-130 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-88 3369752-2 1988 Recent experimental and clinical reports have suggested that beta-2 adrenergic stimulation impairs and beta-2 adrenergic blockade enhances the histamine effect on vascular permeability. Histamine 143-152 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 103-109 92803-4 1979 Fenoterol, a beta 2-sympathomimetic stimulator drug, is shown to be a potent inhibitor of antigen-induced release of histamine. Histamine 117-126 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 2951806-0 1986 Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients. Histamine 0-9 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 104-110 6203844-3 1984 The relationship between the effect of fenoterol and cAMP level is supported by the finding that the beta 2-adrenergic agonist only inhibits the first stage of antigen-induced histamine release and not the release caused by the Ca2+ ionophore, A23187. Histamine 176-185 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 101-107 6197312-4 1983 These results suggest that adrenoceptors in human lung which modulate the immunological release of SRS-A leukotrienes are of the beta 2-subtype as for histamine release. Histamine 151-160 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 129-135 23051-3 1977 But autacoids (serotonin, bradykinin, histamine and prostaglandines) and with the stimulating or inhibiting agents of the beta2 -receptors also begin to be recognized. Histamine 38-47 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 122-127 17196553-9 2007 The effect may involve other mechanisms such as allosteric modulation of beta2-adrenoceptors by the imidazole moiety of histamine. Histamine 120-129 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 73-78 26074818-8 2015 However, we found that histamine modulation is dependent on the amino acid residues alpha1(R120), beta2(Y157), beta2(D163), beta3(V175), and beta3(Q185). Histamine 23-32 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 98-108 26074818-8 2015 However, we found that histamine modulation is dependent on the amino acid residues alpha1(R120), beta2(Y157), beta2(D163), beta3(V175), and beta3(Q185). Histamine 23-32 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 111-121 26074818-9 2015 We showed that the amino acid residues beta2(Y157) and beta3(Q185) mediate the positive modulatory effect of histamine on GABA-induced currents, whereas alpha1(R120) and beta2(D163) form a potential histamine interaction site in GABAARs. Histamine 109-118 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 39-49 26074818-9 2015 We showed that the amino acid residues beta2(Y157) and beta3(Q185) mediate the positive modulatory effect of histamine on GABA-induced currents, whereas alpha1(R120) and beta2(D163) form a potential histamine interaction site in GABAARs. Histamine 199-208 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 39-49 26074818-9 2015 We showed that the amino acid residues beta2(Y157) and beta3(Q185) mediate the positive modulatory effect of histamine on GABA-induced currents, whereas alpha1(R120) and beta2(D163) form a potential histamine interaction site in GABAARs. Histamine 199-208 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 170-180 24900851-2 2014 Determination of activities at the human beta-adrenoreceptors demonstrated a series of highly potent and selective beta2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Histamine 193-202 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 115-120 11549530-10 2001 The additional use of inhaled corticosteroids during the second year resulted in an improved perception of histamine-induced bronchoconstriction (slope alpha) compared with the first year for only the long-acting beta(2)-agonists group (p value 0.036). Histamine 107-116 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 213-219 16172269-4 2005 Similar results were observed on endothelium treated with histamine, which induces P-selectin-dependent rolling and beta2-integrin-dependent adhesion. Histamine 58-67 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 116-121 11998988-7 2002 Each dose of beta2-agonist reduced AR to AMP and histamine. Histamine 49-58 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-18 11908511-5 2002 The aim of this study was to invest gate whether a rebound effect (a pharmacological deterioration effect diminishing after several hours) in FEV1 and PC20 (concentration of histamine causing a 20% fall in FEV1 with regard to baseline) occurred after cessation of regular use of beta2-agonists, and whether this occurred both after short-acting and long-acting beta2-agonists. Histamine 174-183 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 279-284 11908511-5 2002 The aim of this study was to invest gate whether a rebound effect (a pharmacological deterioration effect diminishing after several hours) in FEV1 and PC20 (concentration of histamine causing a 20% fall in FEV1 with regard to baseline) occurred after cessation of regular use of beta2-agonists, and whether this occurred both after short-acting and long-acting beta2-agonists. Histamine 174-183 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 361-366 11549530-12 2001 The additional use of inhaled corticosteroids during chronic use of long-acting beta(2)-agonists improves the perceptive "sensitivity" for changes in FEV(1) during histamine-induced bronchoconstriction, which was not observed for short-acting bronchodilators. Histamine 164-173 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 80-86 8937731-11 1996 The beta 2 agonist, salbutamol inhibited TNF-alpha release from monocytes and histamine release from mast cells whilst having no effect on eosinophil-derived LTB4 release or macrophage superoxide generation. Histamine 78-87 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 10351919-1 1999 Short-acting beta2-agonists provide greater protection against bronchoconstriction induced by adenosine 5"-monophosphate (AMP) than by direct-acting bronchoconstrictors such as histamine and methacholine. Histamine 177-186 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-18 10378545-4 1999 RESULTS: Inhalation of the beta2-agonist was associated with an increase in provocative concentration causing a 20% decrease in FEV1 (PC20) values (geometric mean) from 1.01+/-2.76 to 20.54+/-6.24 mg/mL for methacholine and from 2.29+/-2.26 to 19.82+/-5.93 mg/mL for histamine. Histamine 267-276 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 27-32 9569243-9 1998 The role of cAMP in mediating the histamine effects was supported by the observations that the beta2-agonist salbutamol had effects similar to histamine and that high concentrations of PGE2 mimicked the inhibitory effects of histamine. Histamine 34-43 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 95-100 9438493-1 1997 Beta 2-agonists inhibit the release of preformed mediators such as histamine and newly synthesized mediators such as prostaglandin D2 from mast cells. Histamine 67-76 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 10563469-5 1999 RESULTS: Both beta2-agonists inhibited allergen-induced histamine release and wheal and flare reactions with maximum inhibition of 40-50% at 10(-6) M, a concentration which reduced PGD2 synthesis by approximately 55%. Histamine 56-65 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 14-19 9499814-8 1996 Histamine challenge after beta 2-agonist pre-treatment was associated with increased ventilatory drive in one patient despite the absence of bronchial obstruction, indicating that histamine might directly stimulate afferent airway nerves which cause hyperventilation. Histamine 0-9 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 26-32 8837662-2 1996 In vitro, beta 2-agonists and to a lesser extent corticosteroids have been shown to reduce histamine release. Histamine 91-100 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 10-16 9499814-8 1996 Histamine challenge after beta 2-agonist pre-treatment was associated with increased ventilatory drive in one patient despite the absence of bronchial obstruction, indicating that histamine might directly stimulate afferent airway nerves which cause hyperventilation. Histamine 180-189 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 26-32 8104272-1 1993 Regular inhaled beta 2 agonist causes tolerance to the acute protective effect of beta 2 agonist against bronchoconstriction induced by chemical stimuli such as AMP, histamine, and methacholine. Histamine 166-175 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 16-22 9162320-9 1996 Because the last doses of Ditec were taken 2 hours before the bronchial provocation test with histamine, the increase in tolerance of histamine, mentioned above, was probably only due to the so-called acute effect of beta 2-agonist on BHR. Histamine 94-103 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 217-223 9162320-9 1996 Because the last doses of Ditec were taken 2 hours before the bronchial provocation test with histamine, the increase in tolerance of histamine, mentioned above, was probably only due to the so-called acute effect of beta 2-agonist on BHR. Histamine 134-143 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 217-223 8104272-1 1993 Regular inhaled beta 2 agonist causes tolerance to the acute protective effect of beta 2 agonist against bronchoconstriction induced by chemical stimuli such as AMP, histamine, and methacholine. Histamine 166-175 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-88 1977787-1 1990 Recently, it was suggested that long-term administration of an inhaled beta 2-agonist might increase bronchial hyperresponsiveness (BHR) to histamine, possibly as a consequence of subsensitization to the inhaled beta 2-agonist. Histamine 140-149 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 71-77 1977787-1 1990 Recently, it was suggested that long-term administration of an inhaled beta 2-agonist might increase bronchial hyperresponsiveness (BHR) to histamine, possibly as a consequence of subsensitization to the inhaled beta 2-agonist. Histamine 140-149 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 212-218 8099699-6 1993 Single doses of long-acting beta 2-agonists give a prolonged protection against methacholine- and histamine-induced airway sensitivity of at least 12 hours. Histamine 98-107 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 28-34